Fundrop

The main objective of the FunDrop project is to establish reproducible and scalable technologies for iPSC-based manufacturing and functional characterisation of T-cells by leveraging picodroplet encapsulation technologies. The project will be based on a collaboration between Celyntra Therapeutics (working as Cellistic), a cell therapy CDMO service provider with unique expertise in iPSC biology, immunology, and bioprocess development, and LiveDrop, a pioneer in microfluidics technologies with added value through its technical background in droplet microfluidics, optics, software, instrument development, and droplet bioassays for functional screening.

The FunDrop project aims to generate state-of-the-art and unique processes for T-cell manufacturing and single-cell characterisation. The collaboration is expected to create new positions, grow existing teams, and ultimately improve patient outcomes by increasing accessibility to cell therapy as first line of treatment for tumours. It is also expected to strengthen the Walloon ATMP value chain, positioning the region as a key player in global biotech and pharmaceutical sectors.